Abstract: In an aspect, the present disclosure provides a method for the oxidative coupling of methane to generate hydrocarbon compounds containing at least two carbon atoms (C2+ compounds). The method can include mixing a first gas stream comprising methane with a second gas stream comprising oxygen to form a third gas stream comprising methane and oxygen and performing an oxidative coupling of methane (OCM) reaction using the third gas stream to produce a product stream comprising one or more C2+ compounds.

Abstract: Embodiments of the present disclosure describe catalysts, methods of preparing catalysts, methods of forming hydrocarbons using the catalysts, and the like.

Abstract: Disclosed herein are processes for producing and separating ethane and ethylene. In some embodiments, an oxidative coupling of methane (OCM) product gas comprising ethane and ethylene is introduced to a separation unit comprising two separators. Within the separation unit, the OCM product gas is separated to provide a C2-rich effluent, a methane-rich effluent, and a nitrogen-rich effluent. Advantageously, in some embodiments the separation is achieved with little or no external refrigeration requirement.

Abstract: Disclosed are processes for conversion of a feedstock comprising C8+ aromatic hydrocarbons to lighter aromatic products in which the feedstock and optionally hydrogen are contacted in the presence of the catalyst composition under conversion conditions effective to dealkylate and transalkylate said C8+ aromatic hydrocarbons to produce said lighter aromatic products comprising benzene, toluene and xylene. The catalyst composition comprises a zeolite, a first metal, and a second metal, and is treated with a source of sulfur and/or a source of steam.

Abstract: According to one or more embodiments presently disclosed, a method of catalytically converting polystyrene may include contacting polystyrene with a catalyst to form a product comprising ethylbenzene. The catalyst may include oxidized iron, oxidized cobalt, and oxidized copper. The catalyst may further include a mesoporous support material with pores having an average pore diameter of from 2 nm to 50 nm.

Abstract: Systems and methods of dehydrogenating a hydrocarbon in a fixed bed dehydrogenation unit. A method for dehydrogenating a hydrocarbon is applied to a fixed bed reactor. The hydrocarbon flows to a fixed bed reactor to be dehydrogenated in presence of a catalyst in the fixed bed reactor. The catalyst in the fixed bed reactor is then regenerated. The period for dehydrogenation, the period for catalyst regeneration and the period for total slack time are controlled such that total slack time is less than both half of the period for dehydrogenation and half of the period for regeneration. One of the advantages of the process comes from optimization of the slack time, thereby increasing the catalyst utilization rate and number of reactors concurrently online.

Abstract: Disclosed are processes for conversion of a feedstock comprising C8+ aromatic hydrocarbons to lighter aromatic products in which the feedstock and optionally hydrogen are contacted in the presence of a first and a second catalyst composition under conversion conditions effective to produce said lighter aromatic products comprising benzene, toluene and xylene. In the process, the C8+ aromatic hydrocarbons are dealkylated to form C6-C7 aromatic hydrocarbon and the C2+ olefins formed are saturated. The remaining C8+ aromatic hydrocarbons are transalkylated with the C6-C7 aromatic hydrocarbon. The first and second catalyst compositions each comprise a zeolite, a first metal, and optionally a second metal, and are treated with a source of sulfur and/or a source of steam.

Abstract: Processes and apparatus for making xylenes and phenol are described. Phenol and alkyl phenols are separated from coal derived liquid. The phenol is separated from the alkyl phenols. The alkyl phenols can be reacted with aromatics such as benzene and toluene to make xylenes. The xylenes and other aromatics are then separated from the phenol and alkyl phenols. Para-xylene is separated and recovered using a xylene separation process, and meta-xylene and ortho-xylene are optionally converted to para-xylene through an isomerization reaction.

Abstract: Disclosed is a method for co-producing various alkenyl halides and hydrofluoroalkanes: cis-1-chloro-3,3,3-trifluoropropene is introduced into a first reactor to carry out an isomerization reaction in the presence of a first catalyst, and the reaction product is rectified to obtain a product trans-1-chloro-3,3,3-trifluoropropene; and 30-70 wt % of trans-1-chloro-3,3,3-trifluoropropene and hydrogen fluoride are mixed and then introduced into a second reactor to carry out a reaction in the presence of a second catalyst to obtain a second reactor reaction product; the second reactor reaction product is introduced into a phase separator for separation, and the obtained organic phase is rectified to obtain the products trans-1,3,3,3-tetrafluoropropene, cis-1,3,3,3-tetrafluoropropene and 1,1,1,3,3-pentafluoropropane. The invention has the advantages of simple process, high efficiency, high operation flexibility, less investment and low energy consumption.

Abstract: The invention pertains to a method in which the production of HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and/or of HCFC-122 (1,1,2-trichloro-2,2-difluoroethane) in at least one reaction step takes place in a microreactor. Particularly, in preferred embodiments of the invention pertains to a method in which the production of HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and/or of HCFC-122 (1,1,2-trichloro-2,2-difluoroethane) in at least one reaction step takes place in a microreactor that comprises or is made of SiC (“SiC-microreactor”), or in a microreactor that comprises or is made of an alloy, e.g. such as Hastelloy C.

Abstract: Provided is a method for producing (Z)-1-chloro-2,3,3-trifluoro-1-propene where (E)-1-chloro-2,3,3-trifluoro-1-propene and water can be efficiently removed and (Z)-1-chloro-2,3,3-trifluoro-1-propene with higher purity can be obtained at a higher recovery ratio. The method for producing (Z)-1-chloro-2,3,3-trifluoro-1-propene includes: distilling a distillation composition which contains (Z)-1-chloro-2,3,3-trifluoro-1-propene, (E)-1-chloro-2,3,3-trifluoro-1-propene and water to remove (E)-1-chloro-2,3,3-trifluoro-1-propene and water as an azeotropic composition or an azeotropic-like composition.

Abstract: The present invention provides a composition comprising an HFO compound, the composition having excellent stability with decomposition and oxidation of the HFO compound being inhibited, the composition having improved refrigerating capacity when used as a heat transfer medium, compared with the case in which an HFO compound is used alone. More specifically, the present invention provides a composition comprising at least one HFO compound selected from the group consisting of HFO-1234yf, (E-/Z-)HFO-1234ze, and (E-/Z-)HFO-1225ye; and a chlorine-containing compound, wherein (1) the chlorine-containing compound is at least one member selected from the group consisting of CH2?CHCl, CHF?CHCl, CH2?CFCl, CF3Cl, CH3Cl, CF3CH2Cl, CClF?CHCl, and CHF?CCl2, and (2) the chlorine-containing compound is contained in an amount ranging from 1 to 500000 mass ppm.

Abstract: Compounds with fire extinguishing properties having the formula: wherein R1 is —CR5R6R7 or —CR5R6CR8R9R10 as well as fire extinguishing units including one or more of the compounds.

Abstract: A method for manufacturing calcium diglyceroxide crystals includes at least the following steps: placing at least one calcium element source compound, in particular calcium oxide, in suspension in glycerol or in a homogeneous mixture of glycerol and an anhydrous glycerol solvent, in particular methanol, referred to as the “starting suspension”, the molar ratio being greater than or equal to 2; milling the starting suspension at an ambient temperature of less than or equal to 50° C. in a three-dimensional liquid-phase ball mill for a holding time of 15 minutes or less; recovering, at the outlet of the mill, a suspension of calcium diglyceroxide crystals, and optionally, washing the obtained suspension with a glycerol solvent in order to eliminate any excess glycerol, optionally, drying the suspension of calcium diglyceroxide crystals so as to obtain a powder of calcium diglyceroxide crystals. Also disclosed are uses associated with the calcium diglyceroxide crystals.

Abstract: Some embodiments include a mixture for use as liquid sorbent for methanol or methanol and water in methanol synthesis using carbon monoxide and hydrogen, carbon dioxide and hydrogen or a mixture of hydrogen, carbon monoxide and carbon dioxide as synthesis reactants. The mixture comprises I) a component A) in the form of at least one salt and at least one component B) selected from the group consisting of: B1) a salt of an anion and one, two, or three of the cations of salt A), wherein the number of cations corresponds to an absolute value of a charge number of the respective anion; B2) a salt comprising one or more bis(trifluoromethylsulfonyl)imide anions and another component, wherein a number of bis(trifluoromethylsulfonyl)imide anions corresponds to an absolute value of a charge number of the respective metal cation; and B3) a zwitterionic compound.

Abstract: The invention relates to a novel solid form of diphenol compound. A process for the preparation of diphenol prills having a spherical shape is disclosed. Said process comprising providing a molten composition comprising from 50 to 100 wt. % of a diphenol compound or a mixture of at least two diphenol compounds, and less than 0.1 wt. % of water; forcing said molten composition through at least one droplet generator means to form droplets; and cooling said droplets to form solid diphenol prills. The diphenol prills obtainable by said process are also one subject-matter of the invention.

Abstract: A process for continuous, on-demand production of dilute acrolein liquid on-site, at or near the point of acrolein injection, by the liquid dehydration of glycerol in an improved tubular reactor where non-aqueous glycerol is combined with a heteropolyacid catalyst, including silicotungstic acid, phosphotungstic acid, or phosphomolybdic acid. The acid catalyst is evenly dissolved and dispersed in the glycerol upstream of the reactor vessel. The reaction is conducted in a tubular reactor which is heated to an elevated reaction temperature. The dilute acrolein produced in the tubular reactor is directed downstream, optionally through a liquid-liquid heat exchanger and then an air-liquid heat exchanger to reduce temperature, and then diluted prior to being injected into sulfide contaminated systems (such as oil & gas water floods, water disposal systems, producing oil wells, and fuel oil storage) via a pressure conduit.

Abstract: The present invention relates to a process for purifying acrolein. The process includes the steps of a) splitting a liquid feed stream containing acrolein into at least a first liquid stream and a second liquid stream, b) introducing the first liquid stream with a temperature T1 into a distillation column at a point between the top and the bottom of the distillation column, c) introducing the second liquid stream with a temperature T2 into the distillation column at the top of the distillation column, d) withdrawing an overhead vapor stream enriched in acrolein from the distillation column, and e) withdrawing a bottom stream depleted in acrolein. The temperature T2 of the second liquid stream in step c) is lower than the temperature T1 of the first liquid stream in step b).

Abstract: The present invention generally relates to processes for converting acrylate esters or a derivative thereof to difluoropropionic acid or a derivative thereof. This process is generally performed using fluorine gas in a hydrofluorocarbon solvent.

Abstract: The present invention relates to a process of making a compound of formula (I). Wherein, R is as defined herein.

Abstract: There is described a method of reducing polymer tar build-up in the production of methyl methacrylate and/or methacrylic acid by the acetone cyanohydrin process. In the method a stabiliser is contacted with the amide stage reaction medium. The stabiliser includes a hydrocarbon moiety capable of donating a labile hydrogen atom to a methacrylamide derivative capable of reaction with said labile hydrogen atom under the conditions in the said medium. The method herein is especially useful for the continuous production of methyl methacrylate and/or methacrylic acid.

Abstract: A process for the production of methyl acetate by carbonylating dimethyl ether with carbon monoxide at a temperature of 250 to 350° C. in the presence of a zeolite catalyst and hydrogen such that the molar ratio of hydrogen to carbon monoxide is at least 1, and one or more compounds containing a hydroxyl functional group and in the absence of any added methyl acetate.

Abstract: A phenol compound comprises a phenyl group, a hydroxy group directly bonded to the phenyl group, and at least one polymeric substituent bound to the phenyl group. The polymeric substituent comprises three or more monomers units. A method for producing a polyurethane polymer comprises the steps of (a) providing a polyol; (b) providing a polyisocyanate compound; (c) providing the phenol compound described above; (d) combining the polyol, the polyisocyanate compound, and the phenol compound to produce a reaction mixture; and (e) allowing the polyol and the polyisocyanate compound to react to produce a polyurethane polymer.

Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In some aspects, the present invention relates to polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms. In some aspects, the present invention relates to compositions and methods comprising the polyamine compound. In some aspects, the compounds, compositions, and methods enhance wound healing.

Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

Abstract: The disclosure provides compositions and methods that are useful in removing, lowering, or otherwise controlling hydrogen sulfide and mercaptans. The compositions and methods can be used in any industry where hydrogen sulfide poses problems, such as when dealing with crude oil based, natural gas based, and/or coal based products. In some embodiments, the compositions include one or more alkoxylated amino formaldehyde adducts.

Abstract: This invention relates to a method for producing an alkenyl 1-aminocyclopropane-1-carboxylic acid of Formula I wherein R1 is a protecting group, n is an integer between 1 and 10, and A and B are chiral centres such that when A is S, B is R and when A is R, B is S. The method comprises a stereoselective formation of the cyclopropane moiety by cycloaddition onto a double bond, in a molecule comprising a chiral template, Formula lc. Further provided is the use of Formula I in the production of stapled peptides.

Abstract: A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.

Abstract: The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.

Abstract: The present invention relates to a compound exhibiting inhibitory activity of at least one of malate dehydrogenases I (MDH1) and malate dehydrogenases 2 (MDH2), and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The inventors of the present invention have experimentally confirmed that the compound exhibiting the MDH1 and/or MDH2 inhibitory activity has an inhibitory effect on mitochondrial respiration in cancer cells, an excellent inhibitory effect on cancer cell growth, etc. Thus, the compound of the present invention is expected to be effectively used as a pharmaceutical composition for treating cancer.

Abstract: The present invention relates to a hydrated crystalline form of 2-acrylamido-2-methylpropane sulfonic acid having a 2-theta powder X-ray diffraction diagram comprising peaks at 10.58°, 11.2°, 12.65°, 13.66°, 16.28°, 18.45°, 20°, 20.4°, 22.5°, 25.5°, 25.88°, 26.47°, 28.52°, 30.28°, 30.8°, 34.09°, 38.19°, 40.69°, 41.82°, 43.74°, 46.04° degrees (+/?0.1°). The present invention also relates to a production method for this form of 2-acrylamido-2-methylpropane sulfonic acid and a preparation method for an aqueous solution A of a salt of this form of 2-acrylamido-2-methylpropane sulfonic acid, and the (co)polymer of this form of -acrylamido-2-methylpropane sulfonic acid.

Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the re-crystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.

Abstract: The present disclosure relates to a process for synthesis of mesotrione. The process comprises reacting 4-toluene sulfonyl chloride with alkali metal sulphite and alkali metal bicarbonate to obtain alkali metal toluene-4-sulfinate. The alkali metal toluene-4-sulfinate is reacted with alkali metal salt of monochloroacetic acid to obtain 4-methylsulfonyl toluene. Further, 4-methylsulfonyl toluene is nitrated to obtain 2-nitro-4-methylsulfonyl toluene. 2-nitro-4-methylsulfonyl toluene is oxidized and then halogenated to obtain 2-nitro-4-methylsulfonylbenzoyl halide. 2-nitro-4-methylsulfonylbenzoyl halide is reacted with alkali metal salt of 1,3-cyclohexanedione to obtain 3-(2-Nitro-4-methylsulfonylbenzoyloxy)cyclohexen-1-one which is reacted with base, a third fluid medium and cyanide ion source to obtain an amorphous mesotrione. The present disclosure also discloses the steps of converting the amorphous mesotrione to crystalline mesotrione having purity greater than 99%.

Abstract: The present invention relates to a process for the production of alkali metal salts of dialkyldithiocarbamic acids and to alkali metal salts of dialkyldithiocarbamic acids produced according to said process.

Abstract: The present disclosure provides solid forms of the hydrochloride salt of (5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (Compound-A). In particular, an amorphous form, an ethyl acetate solvate form, a methyl n-butyl ketone solvate form, an anisole solvate form, an isobutyl acetate solvate form, a n-butyl acetate solvate form, a toluene solvate form, a 4-methyl-2-pentanol solvate form, a n-propyl acetate solvate form, a xylene solvate form, Form VIII and Form IX of the salt are disclosed. Processes for the preparation of each of the disclosed forms are also provided.

Abstract: Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

Abstract: The present invention discloses an enantiomeric compound (?)-2-[(2-(4-fluorobenzoyl)phenyl)amine]-3-[(4-(2-carbazole-ethoxy)phenyl)]propionic acid as represented by formula (I), or a pharmaceutical salt thereof, and a manufacturing method of the compound and application of same. The enantiomeric compound demonstrates relatively better activation of RXR/PPAR-, RXR/PPAR- and RXR/PPAR-heterodimer expression and sugar reduction in a db/db mouse model compared to a (+)-enantiomer.

Abstract: The present invention relates to a novel process for preparation of boscalid anhydrate form I and boscalid anhydrate form II.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The invention relates to non-solvated crystals A, B and C of N-(2-aminophenyl)-6-(7-methoxyquinoline-4-oxy)-1-naphthamide and preparation methods thereof. The invention also relates to pharmaceutical compositions containing the crystals, and a use of the crystals in preparation of a medicament for the treatment of a disease associated with abnormal protein kinase activity or abnormal histone deacetylase activity.

Abstract: The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.

Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Abstract: The present invention refers to substituted imidazolium sulfuranes, the use thereof for the transfer of a —CN group or an alkyne group.

Abstract: The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions and mixtures comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Abstract: This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.

Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Abstract: Compounds of Formula I, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP) are also described.

Abstract: The present invention provides a benzotriazole derivative compound represented by a general formula, (wherein R3 represents an alkyl group, and R4 represents an acryloyloxyalkyl group or a methacryloyloxyalkyl group), as a novel compound capable of being suitably used as a highly light-resistant ultraviolet absorber or resin composition that exhibits an ultraviolet-blocking function over a prolonged period of time and that strongly absorbs wavelengths in the ultraviolet light range of 400 nm or less while ensuring little coloration.

Abstract: The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.